Halozyme Reports Q3 Revenue Growth and Raises 2026 Guidance
Halozyme reported Q3 2026 revenue of $493 million, up 39.2% year over year, including royalty revenue of $341 million, up 44%. It raised full-year revenue guidance to $1.86 billion–$1.93 billion and non-GAAP diluted EPS guidance to $8.75–$9.05.
Halozyme Therapeutics, Inc. announced its third-quarter 2026 financial results, reporting revenue of $493 million, a 39.2% increase compared to the same period last year. The company's royalty revenue grew by 44% to $341 million. Driven by these results, management raised its full-year 2026 guidance, now expecting revenue in the range of $1.86 billion to $1.93 billion and non-GAAP diluted earnings per share between $8.75 and $9.05.
The company's reported quarterly non-GAAP earnings of $2.39 per share exceeded analyst consensus estimates.